Publications by authors named "S A Narod"
Background: The lifetime risk of pancreatic cancer in women with a germline mutation in BRCA1 and BRCA2 is not well established. In an international prospective cohort of female carriers of BRCA1 and BRCA2 mutations, the cumulative incidence of pancreatic cancer from age 40 until 80 years was estimated.
Methods: A total of 8295 women with a BRCA1 or BRCA2 mutation were followed for new cases of pancreatic cancer.
Development of the Ontario Hereditary Cancer Research Network, a unified registry as a resource for individuals with inherited cancer syndromes: an observational registry creation protocol.
BMJ Open
November 2024
Article Synopsis
- - In Canada, hereditary cancer care is inconsistent, leading to patients seeing multiple doctors and needing to advocate for their own treatment plans, highlighting the call for a national registry for carriers of cancer-susceptibility genes.
- - The Ontario Hereditary Cancer Research Network (OHCRN) is being established to create a centralized registry in Ontario to collect clinical, genomic, and self-reported data from participants, expected to launch in mid-2025.
- - Ethical approval for the registry has been secured, and the data will be shared in anonymized forms on the OHCRN website and at conferences, aiming to inform health policies and support research in the field.
Genetic testing for breast cancer predisposing genes has expanded beyond BRCA1 and BRCA2 and now includes panels of 20 or more genes. It is now recommended that all women diagnosed with breast cancer at age 65 or below be offered testing for an extended gene panel. The rationale for testing includes personalizing the management of breast cancer according to the mutation found.
View Article and Find Full Text PDFIt is thirty years since the BRCA1 and BRCA2 genes were discovered and genetic testing for BRCA1 and BRCA2 was introduced. Despite increasing awareness of the genetic basis of cancer and our evolving knowledge of effective means of prevention, screening, and treatment for hereditary breast and ovarian cancers, genetic testing is underutilized, and most mutation carriers remain unidentified. In this commentary, we explore possible reasons for why this might be so.
View Article and Find Full Text PDF